Huili Bio is a new generation of synthetic biology enzyme computational design platform. The company integrates scientific research, production and sales, and is committed to the computational design of the core enzyme components of synthetic biological reactions. The company’s specific business is engaged in the research and development, production and marketing of high-tech products such as bioengineering technology research and technology transfer, pharmaceutical intermediates, medical and health care products, nutritional products and enzyme preparations. Recently, Huili Bio completed a round of financing of nearly 300 million yuan, which was jointly led by Legend Capital and Boyuan Capital, followed by Qianji Capital, Yunqi Capital, and Zhongwei Capital, and Taihe Capital served as the exclusive financial advisor. This round of financing will be used to accelerate the construction and operation of large-scale production facilities, the research and development of new product pipelines, and the expansion of talent teams.
This article is reproduced from: https://www.itjuzi.com/investevent/13319327
This site is for inclusion only, and the copyright belongs to the original author.